Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness
Conditions
Interventions
ARGX-113
Placebo
Locations
66
United States
Investigator Site 29
Phoenix, Arizona, United States
Investigator Site 66
Carlsbad, California, United States
Investigator Site 5
Los Angeles, California, United States
Investigator Site 49
Los Angeles, California, United States
Investigator Site 18
Orange, California, United States
Investigator Site 40
Palo Alto, California, United States
Start Date
August 22, 2018
Primary Completion Date
April 6, 2020
Completion Date
April 6, 2020
Last Updated
February 8, 2022
NCT06312644
NCT07247279
NCT06055959
NCT06149559
NCT04833894
NCT06967480
Lead Sponsor
argenx
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions